Reference health

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

https://doi.org/10.1056/nejmoa2023184
CiteStamped reference-health badge
17/17 checkable references clean · checked 2026-07-25

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

6 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.

The 17 checked references that resolve
resolves10.1371/journal.pmed.1003252
COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology
resolves10.1016/S0140-6736(05)66544-0
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
resolves10.1056/NEJMoa2007764
Remdesivir for the Treatment of Covid-19 — Final Report
resolves10.1016/S0140-6736(20)31022-9
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
resolves10.1001/jama.2020.16349
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
resolves10.1056/NEJMoa2015301
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
resolves10.1038/bjc.2011.79
Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care
resolves10.1056/NEJMoa2022926
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
resolves10.1016/S0140-6736(20)32013-4
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
resolves10.1056/NEJMoa2001282
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
resolves10.1016/j.antiviral.2020.104866
Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
resolves10.1093/jac/dkaa195
Lopinavir pharmacokinetics in COVID-19 patients
resolves10.1089/10799900050163226
Pharmacokinetics and Pharmacodynamics of IFN-β1a in Healthy Volunteers
resolves10.1186/s13054-020-03048-5
Interferon beta-1a for COVID-19: critical importance of the administration route
resolves10.1007/s00134-020-06086-3
Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung
resolves10.1128/MCB.00146-10
The Type I Interferon Signaling Pathway Is a Target for Glucocorticoid Inhibition
resolves10.1056/NEJMoa2021436
Dexamethasone in Hospitalized Patients with Covid-19
The 6 references without a DOI — listed, not checked
no DOI — not checkedWorld Health Organization. A coordinated global research roadmap: 2019 novel coronavirus. March 2020 (https://www.who.int/publications/m/item/a-coordinated-global-research-roadmap).
no DOI — not checkedWorld Health Organization. R&D blueprint and Covid-19 (https://www.who.int/teams/blueprint/covid-19).
no DOI — not checkedWorld Health Organization. An international randomised trial of additional treatments for Covid-19 in hospitalised patients who are all receiving the local standard of care (https://www.who.int/publications/m/item/an-international-randomised-trial-of-additional-treatments-for-covid-19-in-hospitalised-patients-who-are-all-receiving-the-local-standard-of-care).
no DOI — not checkedFDA Center for Drug Evaluation and Research. FDA’s approval of Veklury (remdesivir) for the treatment of Covid-19: summary review (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000Sumr.pdf).
no DOI — not checkedAxfors C Schmitt AM Janiaud P et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials. October 22 2020 (https://www.medrxiv.org/content/10.1101/2020.09.16.20194571v2). preprint.
no DOI — not checkedWorld Health Organization. Corticosteroids for COVID-19: living guidance 2 September 2020 (https://apps.who.int/iris/handle/10665/334125).
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-25 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.1056/nejmoa2023184"><img src="https://citestamp.com/citestamped/10.1056/nejmoa2023184/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1056/nejmoa2023184/badge.svg)](https://citestamp.com/citestamped/10.1056/nejmoa2023184)